What Are the Alternatives to Metformin in 2026? A Clinician's Guide

Key Takeaways

• Common alternatives to metformin for type 2 diabetes include GLP-1 receptor agonists (semaglutide, tirzepatide, dulaglutide), SGLT2 inhibitors (empagliflozin, dapagliflozin), DPP-4 inhibitors (sitagliptin), sulfonylureas (glipizide), and insulin.
• For PCOS, alternatives include inositol supplements, GLP-1 receptor agonists (off-label), spironolactone, oral contraceptives, and lifestyle interventions.
• The right alternative depends on your specific diagnosis, comorbidities, weight goals, kidney function, and how you tolerated metformin.
• A 2022 ADA-EASD consensus update recommended GLP-1 receptor agonists or SGLT2 inhibitors as preferred second-line options when there is established cardiovascular or kidney disease, sometimes ahead of metformin (Davies et al., Diabetes Care 2022).
• No alternative is universally "better." Switching from metformin should be a clinician-led decision based on the reason you can't or shouldn't continue it.

Direct answer (40-60 words)

Common alternatives to metformin for type 2 diabetes include GLP-1 receptor agonists (semaglutide, tirzepatide), SGLT2 inhibitors (empagliflozin, dapagliflozin), DPP-4 inhibitors (sitagliptin), sulfonylureas, and insulin. For PCOS, alternatives include inositol, spironolactone, oral contraceptives, and GLP-1 receptor agonists. The right choice depends on your diagnosis, comorbidities, weight goals, and kidney function.

Table of contents

1. The 30-second answer
2. Why patients look for an alternative to metformin
3. Alternatives for type 2 diabetes
4. Alternatives for prediabetes
5. Alternatives for PCOS
6. GLP-1s as a metformin alternative or add-on
7. Side-by-side comparison: efficacy, side effects, cost
8. When metformin is still the right answer
9. How to switch off metformin safely
10. FAQ
11. Sources
12. Footer disclaimers

Why patients look for an alternative to metformin

Metformin has been the first-line oral medication for type 2 diabetes since the early 2000s. It's effective, cheap (often under $10 per month), and has a long safety record. So why do patients search for alternatives?

The most common reasons:

• Gastrointestinal side effects. Metformin causes nausea, diarrhea, abdominal cramping, or metallic taste in 10 to 30% of patients. The extended-release (ER) formulation helps but doesn't eliminate the issue.
• Inadequate glucose control. A1c remains above target despite maximum-tolerated metformin dose.
• Kidney function decline. Metformin is generally avoided when estimated glomerular filtration rate (eGFR) drops below 30 mL/min/1.73m². It's used cautiously between 30 and 45.
• Vitamin B12 deficiency. Long-term metformin use lowers B12 absorption in some patients (Aroda et al., J Clin Endocrinol Metab 2016).
• Weight goals. Metformin is weight-neutral or causes modest weight loss. Patients seeking significant weight loss often turn to GLP-1s or tirzepatide.
• Pregnancy or pregnancy planning. Metformin is sometimes continued in pregnancy and sometimes switched to insulin depending on indication and trimester.
• Drug interactions. Specific contrast media, alcohol use, or certain other medications make metformin a poor fit for some patients.

The "best alternative" depends on which of these reasons applies to you.

Alternatives for type 2 diabetes

Six broad medication classes are alternatives or add-ons to metformin for type 2 diabetes management.

1. GLP-1 receptor agonists

• Examples: semaglutide (Ozempic), tirzepatide (Mounjaro), dulaglutide (Trulicity), liraglutide (Victoza), exenatide (Bydureon)
• Mechanism: stimulate insulin secretion in response to meals, slow gastric emptying, suppress glucagon, reduce appetite
• Typical A1c reduction: 1.0 to 2.0 percentage points
• Weight effect: significant weight loss (5 to 20% depending on agent and dose)
• Common side effects: nausea, vomiting, constipation, slow GI transit
• Considerations: cardiovascular benefit established for several agents (LEADER trial for liraglutide; SUSTAIN-6 for semaglutide; REWIND for dulaglutide)

2. SGLT2 inhibitors

• Examples: empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana)
• Mechanism: increase glucose excretion in urine
• Typical A1c reduction: 0.5 to 1.0 percentage points
• Weight effect: modest weight loss (2 to 4 kg)
• Common side effects: genital yeast infections, urinary tract infections, dehydration, rare diabetic ketoacidosis
• Considerations: cardiovascular and kidney benefit established (EMPA-REG OUTCOME, DAPA-HF, CREDENCE)

3. DPP-4 inhibitors

• Examples: sitagliptin (Januvia), linagliptin (Tradjenta), saxagliptin (Onglyza)
• Mechanism: prevent breakdown of incretin hormones, indirectly raising insulin secretion
• Typical A1c reduction: 0.5 to 0.8 percentage points
• Weight effect: weight-neutral
• Common side effects: well-tolerated, occasional joint pain
• Considerations: convenient daily oral, weaker glucose effect than GLP-1s

4. Sulfonylureas

• Examples: glipizide, glimepiride, glyburide
• Mechanism: stimulate insulin release from pancreatic beta cells
• Typical A1c reduction: 1.0 to 1.5 percentage points
• Weight effect: weight gain
• Common side effects: hypoglycemia (especially with skipped meals)
• Considerations: cheap, oral, but higher hypoglycemia risk and beta-cell exhaustion concerns

5. Thiazolidinediones (TZDs)

• Example: pioglitazone (Actos)
• Mechanism: improve insulin sensitivity in muscle and fat
• Typical A1c reduction: 0.5 to 1.4 percentage points
• Weight effect: weight gain, fluid retention
• Common side effects: edema, heart failure risk, bone fracture risk in postmenopausal women
• Considerations: less commonly used in 2026 due to side-effect profile

6. Insulin

• Examples: glargine, degludec, lispro, aspart, NPH
• Mechanism: replaces or supplements endogenous insulin
• Typical A1c reduction: variable, can be substantial
• Weight effect: weight gain
• Common side effects: hypoglycemia, injection-site reactions
• Considerations: most effective at lowering glucose; requires patient education and monitoring

Alternatives for prediabetes

Prediabetes (A1c 5.7 to 6.4%, or fasting glucose 100 to 125 mg/dL) is treated primarily with lifestyle change. Metformin is sometimes added for high-risk patients. Alternatives:

Lifestyle interventions: The Diabetes Prevention Program (DPP) study showed that intensive lifestyle change (7% body weight loss, 150 minutes per week of moderate physical activity) reduced 10-year diabetes incidence by 58% (Knowler et al., NEJM 2002). Metformin reduced incidence by 31% in the same trial. Lifestyle is more effective than metformin for prediabetes when patients can sustain it.

GLP-1 receptor agonists: Off-label use of semaglutide or tirzepatide for prediabetes is increasing. The STEP and SURMOUNT trials enrolled patients with prediabetes and showed regression to normoglycemia in a meaningful percentage. Coverage for prediabetes is rare; most use is cash-pay.

Bariatric surgery: For patients with obesity (BMI 35+) and prediabetes, bariatric surgery achieves diabetes prevention or remission rates well above medication.

Acarbose: Reduces postprandial glucose by inhibiting carbohydrate absorption. Modest A1c reduction. GI side effects common. Less commonly prescribed in 2026 outside select populations.

Alternatives for PCOS (polycystic ovary syndrome)

Metformin is widely prescribed off-label for PCOS to address insulin resistance, irregular cycles, and (in some cases) weight. Alternatives:

Inositol (myo-inositol and D-chiro-inositol): Over-the-counter supplements with growing evidence for improving insulin sensitivity, ovulation, and metabolic markers in PCOS (Unfer et al., Endocrine Connections 2017). Typical doses: 2 to 4 g of myo-inositol plus 50 to 200 mg of D-chiro-inositol per day. Side-effect profile is benign.

GLP-1 receptor agonists: Off-label use of semaglutide and tirzepatide for PCOS-related weight management is common in 2026. Studies show improvement in insulin resistance, weight, and menstrual regularity (Salamun et al., Eur J Endocrinol 2018). Not FDA-approved for PCOS.

Spironolactone: Anti-androgen that addresses PCOS hirsutism, acne, and androgenic alopecia. Often combined with oral contraceptives. Not a glucose intervention.

Oral contraceptives: Regulate menstrual cycles, reduce androgen-driven symptoms. First-line for PCOS patients not seeking pregnancy.

Lifestyle interventions: 5 to 10% weight loss in patients with PCOS often restores ovulation and improves metabolic markers, in some cases more effectively than medication.

GLP-1s as a metformin alternative or add-on

GLP-1 receptor agonists are increasingly the default second-line therapy when metformin alone isn't enough. The 2022 ADA-EASD consensus statement recommended GLP-1s or SGLT2 inhibitors as preferred agents in patients with established cardiovascular disease, kidney disease, or heart failure, sometimes alongside or in place of metformin (Davies et al., Diabetes Care 2022).

When a clinician might recommend a GLP-1 instead of metformin:

• Persistent metformin GI intolerance
• Weight loss is a primary clinical goal
• Established atherosclerotic cardiovascular disease
• Chronic kidney disease (with semaglutide or dulaglutide; some agents have specific renal benefit)
• A1c well above target despite lifestyle and metformin

When metformin is still added alongside a GLP-1:

• A1c remains above target on GLP-1 alone
• Cost or coverage favors metformin combination
• Patient tolerates both well

For patients exploring compounded GLP-1s as a metformin alternative or add-on, the considerations are similar to brand-name GLP-1s but the products are not FDA-approved. See /articles/cost-and-insurance/cheap-glp-1/ for pricing and our compounded medication notice in the footer.

Side-by-side comparison: efficacy, side effects, cost

Cash prices are pre-coupon. Insurance copays vary widely.

When metformin is still the right answer

For many patients, metformin remains the right first-line choice. It's:

• Cheap (often $4 per month at major pharmacies)
• Effective (1 to 1.5 percentage point A1c reduction)
• Backed by decades of safety data
• Possibly cardio-protective (UK Prospective Diabetes Study)
• Compatible with most other diabetes medications

If the only issue is GI side effects, switching from immediate-release to extended-release (ER) metformin or splitting doses with food helps in many patients before considering an alternative.

If kidney function is the issue, dose-adjusted metformin is sometimes still appropriate down to eGFR 30. Below 30, alternatives become necessary.

If weight loss is the primary goal, layering a GLP-1 onto metformin is often more effective than switching off metformin entirely.

The "right alternative to metformin" question deserves a clinical conversation, not a self-prescription change.

How to switch off metformin safely

If you and your clinician decide to switch:

1. Identify the replacement medication based on the reason for switching (GI tolerance, kidney function, weight goals, glucose control).
2. Don't stop metformin abruptly if your A1c is currently controlled on it. Sudden discontinuation can lead to glucose excursions over the following weeks.
3. Start the new medication at a starting dose. Most diabetes medications titrate up over weeks.
4. Overlap for 2 to 4 weeks if your clinician advises. This avoids a glucose gap during titration.
5. Monitor blood glucose more frequently during the switch (fingerstick or CGM if available).
6. Recheck A1c at 3 months to confirm the new regimen is working.
7. Watch for new side effects specific to the replacement medication (nausea with GLP-1s, UTIs with SGLT2s, hypoglycemia with sulfonylureas).

For PCOS or prediabetes patients, the switch process is less urgent because A1c is not the primary monitoring metric. Symptom resolution (regular cycles, weight changes, energy) is the marker.

FAQ

What is the best alternative to metformin?

The best alternative depends on why you're switching. For type 2 diabetes with GI intolerance to metformin, extended-release metformin or a GLP-1 receptor agonist is often the next step. For diabetes with established cardiovascular disease, a GLP-1 or SGLT2 inhibitor is preferred. For PCOS, inositol supplements or a GLP-1 are common alternatives.

Is there a natural alternative to metformin?

Inositol (myo-inositol plus D-chiro-inositol) has the strongest evidence among supplements for improving insulin sensitivity, particularly in PCOS. Berberine has shown modest glucose-lowering effects in small studies. Lifestyle interventions (sustained 7% weight loss, 150 minutes per week of moderate exercise) outperformed metformin in the Diabetes Prevention Program for prediabetes prevention.

Is a GLP-1 better than metformin for diabetes?

A GLP-1 typically lowers A1c by 1.0 to 2.0 percentage points; metformin lowers it by 1.0 to 1.5. GLP-1s also produce significant weight loss and have established cardiovascular benefit. Metformin is far cheaper and has decades of safety data. For most patients, the choice depends on weight goals, comorbidities, cost, and tolerance.

Can I take a GLP-1 instead of metformin?

Yes, with a prescriber's guidance. Many patients use a GLP-1 as monotherapy or in place of metformin. Some clinicians prefer to layer a GLP-1 on top of metformin for combined effect. The decision depends on A1c, weight, comorbidities, and how you tolerated metformin.

What can I take instead of metformin for PCOS?

Inositol supplements (myo-inositol 2 to 4 g plus D-chiro-inositol 50 to 200 mg daily) have the strongest evidence. GLP-1 receptor agonists (off-label) are increasingly used for PCOS-related insulin resistance and weight. Spironolactone addresses androgenic symptoms. Oral contraceptives regulate cycles. Lifestyle change is foundational.

What can I take instead of metformin for prediabetes?

Lifestyle change (5 to 7% weight loss, 150 minutes per week of moderate activity) reduced diabetes incidence by 58% in the Diabetes Prevention Program. GLP-1 receptor agonists are used off-label and have strong weight-loss data in prediabetes. Acarbose is a less common option.

Why does metformin upset my stomach?

Metformin's GI side effects (nausea, diarrhea, cramping) come from changes in gut motility, glucose absorption, and microbiome composition. Extended-release metformin reduces side effects in many patients. Taking metformin with food and slowly titrating the dose also helps.

Is berberine an alternative to metformin?

Berberine has shown modest glucose-lowering effects in small randomized studies (typical A1c reduction 0.5 to 1.0 percentage points). It's not FDA-approved for diabetes. Quality varies by supplement brand. It can interact with many medications. It's not a clinical substitute for metformin in established type 2 diabetes without medical supervision.

Can I stop metformin if I'm controlled?

Some patients with prediabetes or early type 2 diabetes can discontinue metformin after sustained weight loss and lifestyle change reverse their hyperglycemia. This should be done under clinical guidance with A1c monitoring. Diabetes is not "cured"; it's in remission, and recurrence is common if lifestyle slips.

Does insurance cover GLP-1s as a metformin alternative?

For type 2 diabetes, most plans cover Ozempic, Mounjaro, Trulicity, or similar GLP-1s with prior authorization, often after a metformin trial. For PCOS or prediabetes, GLP-1 coverage is rare; most patients pay cash or use compounded options.

What's cheaper than metformin?

Almost nothing among prescription diabetes medications. Metformin at $4 per month is one of the cheapest medications in U.S. retail pharmacy. Older sulfonylureas (glipizide, glimepiride) are similarly priced. Most other classes (GLP-1, SGLT2, DPP-4) are far more expensive.

Can I take metformin and a GLP-1 together?

Yes. This combination is common and well-studied. Metformin and GLP-1s have different mechanisms and complementary effects. The combination often produces better A1c reduction and weight loss than either alone. Side effects can stack (especially GI), so careful titration helps.

Related guides

• Metformin Substitutes: When You Can't Take Metformin, What a Clinician Replaces It With
• Metformin Alternatives: The Complete Evidence-Based Guide to What Works (and What Doesn't) in 2026
• What Are the Best Alternatives to Metformin in 2026?
• Alternatives to Metformin: A Practical Guide to Other Type 2 Diabetes Medications
• Metformin Alternatives in 2026: Prescription Options, Lifestyle Tools, and the Supplements With Real Evidence
• Natural Metformin: The Evidence Behind Berberine, Inositol, and Other Alternatives to Pharmaceutical Blood Sugar Control

Sources

1. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes (ADA-EASD consensus). Diabetes Care. 2022;45(11):2753-2786.
2. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (Diabetes Prevention Program). N Engl J Med. 2002;346:393-403.
3. Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency. J Clin Endocrinol Metab. 2016;101(4):1754-1761.
4. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER trial). N Engl J Med. 2016;375:311-322.
5. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
6. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373:2117-2128.
7. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE). N Engl J Med. 2019;380:2295-2306.
8. Unfer V, Carlomagno G, Dante G, et al. Effects of myo-inositol in women with PCOS: a systematic review. Endocrine Connections. 2017;6(8):647-658.
9. Salamun V, Jensterle M, Janez A, et al. Liraglutide increases IVF pregnancy rates in obese PCOS women. Eur J Endocrinol. 2018;179(1):1-11.
10. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin (UKPDS 34). Lancet. 1998;352:854-865.
11. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
12. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Victoza, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro, Zepbound, Trulicity, and Jardiance are registered trademarks of Eli Lilly and Company or Boehringer Ingelheim. Farxiga, Invokana, Januvia, Tradjenta, Onglyza, Actos, Bydureon, and other brand names referenced are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.